Identification and metastatic potential of tumor-initiating cells in malignant rhabdoid tumor of the kidney

Clinical Cancer Research

Volumn 15, Issue 9, 2009, Pages 3014-3022

  Yanagisawa, Satohiko ^a   Kadouchi, Ichiro ^a   Yokomori, Kinji ^a   Hirose, Masao ^b   Hakozaki, Michiyuki ^c   Hojo, Hiroshi ^c   Maeda, Kosaku ^a   Kobayashi, Eiji ^a   Murakami, Takashi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b NARUTO UNIVERSITY OF EDUCATION   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CHEMOKINE RECEPTOR CXCR4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CASE REPORT; CONTROLLED STUDY; DISTANT METASTASIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INFANT; KIDNEY TUMOR; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOID TUMOR; WESTERN BLOTTING; XENOTRANSPLANTATION;

ANIMALS; ANTIGENS, CD; BLOTTING, WESTERN; FEMALE; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; INFANT; KIDNEY NEOPLASMS; LUCIFERASES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; NEOPLASTIC CELLS, CIRCULATING; PEPTIDES; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOID TUMOR; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; WHOLE BODY IMAGING;

EID: 65649094099     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2237     Document Type: Article

References (48)

1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
2. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004;432:324-331.
3. Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 2007;7:791-799.
4. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007;23:675-699.
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-3988.
6. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
7. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-110.
8. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-115.
9. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1:313-323.
10. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-10951.
11. Beckwith J, Palmer N. Histopathology and prognosis of Wilms' tumor: Results of the First National Wilms' Tumor Study. Cancer1978;41:1937-1948.
12. Palmer N, Sutow W. Clinical aspects of the rhabdoid tumor of the kidney. A report of the National Wilms' Tumor Study Group. Med Pediatr Oncol 1983;11:242-245.
13. Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998;394:203-206.
14. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999;59:74-79.
15. Tomlinson GE, Breslow NE, Dome J, et al. Rhabdoid tumor of the kidney in the National Wilms' Tumor Study: age at diagnosis as a prognostic factor. J Clin Oncol 2005;23:7641-7645.
16. Weeks DA, Beckwith JB, Mierau GW, Luckey DW. Rhabdoid tumor of the kidney. A report of 111 cases from the National Wilms' Tumor Study Pathology Center. Am J Surg Pathol 1989;13:439-458.
17. Murakami T, Maki W, Cardones AR, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002;62:7328-7334.
18. Garvin AJ, Re GG, Tarnowski BI, Hazen-Martin DJ, Sens DA. The G401 cell line, utilized for studies of chromosomal changes in Wilms' tumor, is derived from a rhabdoid tumor of the kidney. Am J Pathol 1993;142:375-380.
19. Hirose M, Yamada T, Abe T, et al. Establishment and characterization of two cultured cell lines derived from malignant rhabdoid tumors of the kidney. Int J Cancer 1996;67:218-223.
20. Hakozaki M, Hojo H, Sato M, et al. Establishment and characterization of a new cell line, FRTK-1, derived from human malignant rhabdoid tumor of the kidney, with overexpression of epidermal growth factor receptor and cyclooxygenase-2. Oncol Rep 2006;16:265-271.
21. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T. Antitumor activity of IFN-λ inmurine tumor models. J Immunol 2006;176:7686-7694.
22. Murakami T, Sato A, Chun NA, et al. Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma. J Invest Dermatol 2008;128:1506-1516.
23. Higashino K, Narita T, Taga T, Ohta S, Takeuchi Y. Malignant rhabdoid tumor shows a unique neural differentiation as distinct from neuroblastoma. Cancer Sci 2003;94:37-42.
24. Contag CH, Bachmann MH. Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng 2002;4:235-260.
25. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 2008;452:580-589.
26. Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997;90:5013-5021.
27. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002-5012.
28. + hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006;351:820-824.
29. Yin S, Li J, Hu C, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007;120:1444-1450.
30. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15:504-514.
31. - metastatic colon cancer cells initiate tumors. J Clin Invest 2008;118:2111-2120.
32. Shmelkov SV, Jun L, St Clair R, et al. Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 2004;103:2055-2061.
33. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:540-550.
34. Murakami T, Cardones AR, Hwang ST. Chemokine receptor and melanoma metastasis. J Dermatol Sci 2004;36:71-78.
35. Rubin JB, Kung AL, Klein RS, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 2003;100:13513-13518.
36. Zeelenberg IS, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003;63:3833-3839.
37. Koshiba T, Hosotani R, Miyamoto Y, et al. Expression of stromal cell-derived factor 1and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 2000;6:3530-3535.
38. Scala S, Ottaiano A, Ascierto PA, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005;11:1835-1841.
39. Kim J, Takeuchi H, Lam ST, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005;23:2744-2753.
40. Xu F, Wang F, Di M, et al. Classification based on the combination of molecular and pathologic predictors is superior to molecular classification on prognosis in colorectal carcinoma. Clin Cancer Res 2007;13:5082-5088.
41. Dalerba P, Clarke MF. Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell 2007;1:241-242.
42. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545.
43. Coussens LM, Werb Z. Inflammatory cells and cancer: think different! J Exp Med 2001;193:F23-6.
44. Burns JM, Summers BC, Wang Y, et al. A novel chemokine receptor for SDF-1and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006;203:2201-2213.
45. Miao Z, Luker KE, Summers BC, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A 2007;104:15735-15740.
46. Wang J, Shiozawa Y, Wang J, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008;283:4283-4294.
47. Katsumi Y, Kuwahara Y, Tamura S, et al. Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity. Clin Cancer Res 2008;14:1192-1199.
48. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature 2008;451:345-349.